clinical trial · NCT07174310
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Parkinson's DiseasePrasinezumabPlacebo
brief summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
started
Nov 24, 2025
primary completion
Jun 30, 2029
completion
Jun 30, 2031
last updated
Jul 6, 2026
official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol